What is TearSolutions?
TearSolutions specializes in creating novel treatments for ocular surface diseases, with a primary focus on its first-in-class peptide therapy, Lacripep. This innovative treatment is designed to restore the health of the ocular surface by addressing deficiencies in tear proteins, particularly benefiting patients with conditions such as primary Sjögren's Syndrome. The company targets the significant market of individuals affected by dry eye disease, a condition prevalent among older adults and often exacerbated by environmental factors. With a robust leadership team and ongoing clinical trials, TearSolutions is strategically positioned to drive advancements in the ophthalmology sector.
How much funding has TearSolutions raised?
TearSolutions has raised a total of $23.9M across 5 funding rounds:
Series A
$3M
Private Equity
$3.4M
Private Equity
$8.1M
Debt
$6.4M
Series B
$3M
Series A (2015): $3M with participation from LaunchCapital, Santen Pharmaceuticals Co., Ltd., and CIT
Private Equity (2017): $3.4M, investors not publicly disclosed
Private Equity (2017): $8.1M, investors not publicly disclosed
Debt (2019): $6.4M featuring UVa Seed Fund, PharmStandard Ventures, VTC Innovation Fund, and Medarva Foundation
Series B (2024): $3M, investors not publicly disclosed
Key Investors in TearSolutions
LaunchCapital
LaunchCapital is a venture capital firm dedicated to supporting entrepreneurs at the seed and early stages of their development. They provide hands-on assistance and have invested in over 200 companies since 2008, leveraging seed and growth investments.
Santen Pharmaceuticals Co., Ltd.
Santen Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company with a strong specialization in ophthalmology, holding a leading position in the global market and selling products in over 50 countries.
CIT
The Center for Innovative Technology (CIT) is a non-profit organization focused on creating technology-based economic development strategies. It supports technology start-up companies by bridging gaps in commercialization and seed funding.
What's next for TearSolutions?
The recent major strategic investment marks a pivotal moment for TearSolutions, indicating a transition towards scaling its therapeutic solutions and expanding its market reach. This capital infusion is expected to accelerate the company's clinical trial progression and support the commercialization efforts for Lacripep. As TearSolutions moves through its growth trajectory, further strategic partnerships and financing rounds may be anticipated to solidify its position as a leader in ocular surface disease treatment. The company's focus on addressing unmet needs in ophthalmology positions it for sustained development and potential market disruption.
See full TearSolutions company page
